Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Ralimetinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLYRad
- 09 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 09 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2017 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.